Skip to main content
Explore URMC
menu

100510 / Duke University / Consolidation RT in DLBcL / Louis Constine

Research Question:
Evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity .

Basic Study Information

Purpose:
This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity . Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET-CT scan following rituximab - containing chemotherapy.

Location: University of Rochester James P. Wilmot Cancer Institute
Study Reference #: RLYM19037

Lead Researcher (Principal Investigator)

Lead Researcher:  Louis Constine

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search